July 8, 2019
June 10, 2019
ATRYS intends to lead the Smart / Big Data in health with the integration of Real Life Data
ATRYS HEALTH, S.A. ("ATRYS"), a company listed on the MAB and included in the IBEX® MAB-15 index, dedicated to diagnostic services and medical treatments of excellence, has closed the acquisition of 100% of REAL LIFE DATA SLU, leader in Smart/Big Data in the health sector in Spain.
The transaction is a determining step for ATRYS and consolidates it as a reference in the provision of Smart/Big Data services and data management in the health sector. This acquisition will allow adding a new dimension to the medical services currently provided by ATRYS, with which it generates more than one million diagnostic reports per year. The operation will enhance the work of ATRYS in the field of predictive medicine, reinforcing its R&D area and developing knowledge about the evolution and dimension of pathologies, trends in diagnoses and treatments.
March 4, 2019
Financial Times includes Atrys Health among the 1000 fastest growing companies in Europe
Atrys Health, S.A., a company dedicated to the provision of diagnostic services and precision medical treatments, has been included in the 'FT 1000: Europe's Fastest-Growing Companies' ranking, prepared by the prestigious British newspaper Financial Times. A study that highlights the companies that act as a driving force of the European economy.
December 5, 2018
Atrys Health winner at SME Cap Awards 2018 of the European Commission
Madrid, December 5, 2018.- Atrys Health, SA, a company that debuted as a listed company in the MAB in July 2016, rose yesterday with the first place in the "Rising Star" category of the Small and MidCap Awards 2018, organized by the European Commission and whose ceremony took place in Brussels.
This award is given to that listed company that during the year 2018 has stood out for being an "exceptional actor" in the subgroup of listed SMEs with a market capitalization of up to 50 million euros. The evaluation of the members of the jury focuses on the potential for business growth, the attention of the company in the field of corporate social responsibility and the good performance of the candidates' stock market together with their potential for future revaluation of the price of their shares.
October 19, 2018
ATRYS HEALTH integrates Llebalust Pathology in its Group
ATRYS (ATRY), a company listed on the MAB and included in the IBEX® MAB-15 index, dedicated to the provision of diagnostic services and medical treatments of excellence, today closed the acquisition of a significant participation in Llebalust Pathology, S.L. ("LLEBALUST"), one of the main independent operators of Pathology in Spain.
In this way, Atrys consolidates a turnover of 3.8 million euros and 920 thousand euros of Ebitda, incorporating into the balance sheet of the Group a company without financial indebtedness.